Search research articles
Contact Us
Filters
Showing results (1-10 of 21) with videos related to
Page
of 3
Sort By:
Advances in Therapy
|
August 21, 2024
Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis
Brett Hauber, Agnes Hong, Elke Hunsche, et al.
Clinical Genitourinary Cancer
|
September 13, 2024
Fatigue Management in Advanced Prostate Cancer: Real-World Insights From Qualitative Interviews With Patients
Stephen J Freedland, Marty Chakoian, Ted Wells, et al.
Future Oncology (London, England)
|
April 7, 2025
Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US
Jason Hafron, Agnes Hong, Michael J Ryan, et al.
Prostate Cancer and Prostatic Diseases
|
September 13, 2024
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment
Stephen J Freedland, Wei Gao, Angela Lax, et al.
The Patient
|
March 12, 2026
Stated Preferences for Systemic Treatments for Prostate Cancer: A Targeted Review of the Discrete-Choice Experiment Literature
Neeraj Agarwal, Brett Hauber, Agnes Hong, et al.
Cancer Medicine
|
November 2, 2021
Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration
Stephen J Freedland, Rickard Sandin, Janvi Sah, et al.
Urology Practice
|
August 15, 2025
Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the U.S. Medicare Fee-for-Service Population
Rana R McKay, Agnes Hong, Juan F Razo, et al.
Prostate Cancer and Prostatic Diseases
|
December 14, 2022
Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting
Stephen J Freedland, Agnes Hong, Nader El-Chaar, et al.
Future Oncology (London, England)
|
July 29, 2024
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States
Umang Swami, Agnes Hong, Brandon Diessner, et al.
Journal of Patient Experience
|
August 28, 2020
How Oncologists Perceive the Availability and Quality of Information Generated From Patient-Reported Outcomes (PROs)
Michael Shea, Céline Audibert, Mark Stewart, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 21) with videos related to
Sort By:
Page
of 3
Advances in Therapy
|
August 21, 2024
Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis
Brett Hauber, Agnes Hong, Elke Hunsche, et al.
Clinical Genitourinary Cancer
|
September 13, 2024
Fatigue Management in Advanced Prostate Cancer: Real-World Insights From Qualitative Interviews With Patients
Stephen J Freedland, Marty Chakoian, Ted Wells, et al.
Future Oncology (London, England)
|
April 7, 2025
Study of persistence and adherence to ADT in prostate cancer: relugolix, degarelix, and GnRH agonists in the US
Jason Hafron, Agnes Hong, Michael J Ryan, et al.
Prostate Cancer and Prostatic Diseases
|
September 13, 2024
Real-world outcomes following biochemical recurrence after definitive therapy with a short prostate-specific antigen doubling time: potential role of early secondary treatment
Stephen J Freedland, Wei Gao, Angela Lax, et al.
The Patient
|
March 12, 2026
Stated Preferences for Systemic Treatments for Prostate Cancer: A Targeted Review of the Discrete-Choice Experiment Literature
Neeraj Agarwal, Brett Hauber, Agnes Hong, et al.
Cancer Medicine
|
November 2, 2021
Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration
Stephen J Freedland, Rickard Sandin, Janvi Sah, et al.
Urology Practice
|
August 15, 2025
Adherence and Persistence on Relugolix for the Treatment of Prostate Cancer in the U.S. Medicare Fee-for-Service Population
Rana R McKay, Agnes Hong, Juan F Razo, et al.
Prostate Cancer and Prostatic Diseases
|
December 14, 2022
Prostate-specific antigen response and clinical progression-free survival in Black and White men with chemotherapy-naïve metastatic castration-resistant prostate cancer treated with enzalutamide in a real-world setting
Stephen J Freedland, Agnes Hong, Nader El-Chaar, et al.
Future Oncology (London, England)
|
July 29, 2024
Treatment patterns and outcomes in patients with nonmetastatic castration-resistant prostate cancer in the United States
Umang Swami, Agnes Hong, Brandon Diessner, et al.
Journal of Patient Experience
|
August 28, 2020
How Oncologists Perceive the Availability and Quality of Information Generated From Patient-Reported Outcomes (PROs)
Michael Shea, Céline Audibert, Mark Stewart, et al.
Page
of 3